Form 4: ClearPoint Neuro CFO Exercises Stock Options

ClearPoint Neuro's Chief Financial Officer, Danilo D'Alessandro, exercised 3,555 stock options at $8.1 per share, increasing his direct beneficial ownership.

Summary

• Danilo D'Alessandro, Chief Financial Officer of ClearPoint Neuro, Inc., exercised 3,555 stock options on November 21, 2025.
• The exercise price for these options was $8.1 per share.
• Mr. D'Alessandro paid the exercise price in cash and has retained all shares received from the exercise, with no shares sold in connection with this transaction.
• Following this transaction, Mr. D'Alessandro directly beneficially owns 69,923 shares of Common Stock.
• He also beneficially owns 12,082 derivative securities (stock options) after this transaction.
• The exercised options were granted on March 6, 2023, with a vesting schedule of 20% on the first anniversary, 40% on the second anniversary, and 40% on the third anniversary of the grant date, and an expiration date of March 6, 2033.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the CFO exercising options and retaining all shares, indicating confidence in the company's future. No negative aspects were reported.

Positives

• The Chief Financial Officer increased his direct beneficial ownership of ClearPoint Neuro common stock by 3,555 shares.
• Mr. D'Alessandro paid cash for the option exercise, demonstrating a direct investment.
• No shares were sold in connection with this transaction, indicating a commitment to holding the company's equity.

Future Outlook

The Chief Financial Officer's decision to exercise options and hold all acquired shares, rather than selling any, suggests confidence in the company's future performance and long-term value.

Industry Context

Insider transactions, such as option exercises where shares are retained, are often viewed by the market as a positive signal, indicating management's belief in the company's prospects. This aligns with general market sentiment that insider buying or holding reflects confidence.

Stakeholder Impact

• Shareholders may view the CFO's increased direct ownership as a positive sign of management's alignment with shareholder interests and belief in the company's long-term value.

Next Steps

• Future vesting of remaining stock options on March 6, 2026 (40% of total shares).

Key Dates

Recommendation

The Chief Financial Officer's decision to exercise stock options and retain all acquired shares, rather than selling them, signals strong insider confidence in ClearPoint Neuro's future prospects. This action suggests management believes the stock has further upside potential. While not a new discretionary market purchase, the retention of shares is a positive indicator for existing shareholders, supporting a 'hold' recommendation for those already invested, and potentially a closer look for new investors.

Keywords

ClearPoint Neuro, CLPT, Insider Transaction, Stock Options, CFO, Beneficial Ownership, SEC Form 4, Equity Compensation